RETRACTION

Pathol. Oncol. Res., 25 May 2023
https://doi.org/10.3389/pore.2023.1611110

Retraction: MiR-543 Inhibits the Migration and Epithelial-To-Mesenchymal Transition of TGF-β-Treated Endometrial Stromal Cells via the MAPK and Wnt/β-Catenin Signaling Pathways

www.frontiersin.orgPathology and Oncology Research Editorial Office*

A Retraction of the Original Research Article
MiR-543 Inhibits the Migration and Epithelial-To-Mesenchymal Transition of TGF-β-Treated Endometrial Stromal Cells via the MAPK and Wnt/β-Catenin Signaling Pathways

by Wang L, Liu D, Wei J, Yuan L, Zhao S, Huang Y, Ma J and Yang Z (2021). Pathol. Oncol. Res. 27:1609761. doi: 10.3389/pore.2021.1609761

Following publication, concerns were raised regarding data misrepresentation. In particular, with the Western blot in Figure 4A, which also appears in Zhang et al. [1]. Following provision of raw data by the authors, the Editor in Chief concluded that the article’s conclusions and assertions were not sufficiently supported by the findings from the material provided; therefore, the article has been retracted.

Reference

1. Zhang, M, Liu, S, Fang, L, Wang, G, and Yin, L. Asiaticoside inhibits renal fibrosis development by regulating the miR-142-5p/ACTN4 axis. Biotechnol Appl Biochem (2022) 69:313–22. doi:10.1002/bab.2110

PubMed Abstract | CrossRef Full Text | Google Scholar

Citation: Pathology and Oncology Research Editorial Office (2023) Retraction: MiR-543 Inhibits the Migration and Epithelial-To-Mesenchymal Transition of TGF-β-Treated Endometrial Stromal Cells via the MAPK and Wnt/β-Catenin Signaling Pathways. Pathol. Oncol. Res. 29:1611110. doi: 10.3389/pore.2023.1611110

Received: 10 February 2023; Accepted: 10 February 2023;
Published: 25 May 2023.

Copyright © 2023 Pathology and Oncology Research Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Pathology and Oncology Research Editorial Office, editorialoffice@por-journal.com